Studies related to Pain and Rose Hip

The Anti-inflammatory Properties Of Rose-hip

Supplementation of either 10g or 45g rose hip powder extract to otherwise healthy men for one month was able to reduce C-reactive protein concentrations (up to 30-35%) and reduced chemotaxis of polymorphonuclear leukocytes by up to 50% (low dose) and 65% (high dose). It was also noted in four of the persons characterized by high physical work (due to their occupation) that rosehip alleviated joint discomfort.

All changes returned to baseline values after cessation of rosehip supplementation.

The Effects Of Rose Hip (Rosa Canina) On Plasma Antioxidative Activity And C-reactive Protein In Patients With Rheumatoid Arthritis And Normal Controls: A Prospective Cohort Study

Supplementation of 10.5g rose hip powder daily for four weeks in persons with rheumatoid arthritis as well as a group of healthy controls failed to reduce symptoms of rheumatoid arthritis or to influence biomarkers (red blood cell antioxidant enzymes or C-reactive protein) relative to baseline; no placebo group was used in this study.

A Herbal Remedy, Hyben Vital (stand. Powder Of A Subspecies Of Rosa Canina Fruits), Reduces Pain And Improves General Wellbeing In Patients With Osteoarthritis--a Double-blind, Placebo-controlled, Randomised Trial

In persons with osteoarthritis of varying joints given 5g of rose hip powder daily for three months in a double blind crossover study (no time between crossover periods), noted that supplementation of rose hip during the second period showed benefits relative to the first period of supplementation with placebo although the group assigned rosehip initially found benefits which seemed to persist during the three months on placebo.

Rose Hip Herbal Remedy In Patients With Rheumatoid Arthritis - A Randomised Controlled Trial

Rose hip supplementation at 5g for six months in persons with rheumatoid arthritis appeared to show benefits on a health assessment questionnaire (HAQ) at six months yet not three. While there was a trend to improve overall symptoms of rheumatism by clinician rating and DAS-28 rating, the rating scale selectively looking at pain in joints (HAQ patient pain scale) failed to find any benefit. C-reactive protein trended to decrease but failed to reach statistical significance.

Degree of improvement on the global symptoms reached 30% (physician rating) and 19% (DAF-28) relative to baseline values.